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Abstract 
Aim: Lynch Syndrome (LS) is associated with an increased risk of developing 
endometrial carcinoma (EC) and ovarian carcinoma (OC). There is 
considerable variability in current practices and opinions related to screening 
newly diagnosed patients with EC/OC for LS. An online survey was 
undertaken to explore the extent of these differences. 
Methods: An online questionnaire was developed by a panel of experts and 
sent to all members of the British Association of Gynaecological Pathologists 
(BAGP) and the International Society of Gynecological Pathologists (ISGyP). 
Anonymised results were received and analyzed. 
Results: Thirty-six BAGP and 44 ISGyP members completed the survey. 
More than 90% of respondents were aware of the association of LS with both 
EC and OC, but 34% were not aware of specific guidelines for LS screening. 
Seventy-one percent of respondents agreed that universal screening for LS 
should be carried out in all newly diagnosed EC cases, with 
immunohistochemistry (IHC) alone as the preferred approach. Only 36% of 
respondents currently performed IHC or microsatellite instability testing on all 
newly diagnosed EC, with most of the remaining respondents practicing 
selective screening, based on clinical or pathological features or both. A 
significant minority of respondents (35%) believed that patient consent was 
required before performing MMR IHC. Almost all respondents favored use of 
standardized terminology for reporting MMR staining results and this is 
proposed herein.  
Conclusion: There is wide support for universal LS screening in patients with 
EC, but this survey highlights areas of considerable variation in practice. 
 
 
 
Key words: Lynch Syndrome, endometrial carcinoma, mismatch repair, 
screening, TCGA, immunohistochemistry, terminology, consent 
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Introduction:  
Lynch Syndrome (LS) is an inherited predisposition to a variety of cancers 
caused by a pathological mutation within the mismatch repair (MMR) genes 
(MLH1, MSH2, MSH6 PMS2) (1). LS is a grossly under-diagnosed condition 
with an estimated 95% of cases being unrecognised (2). Women with LS have 
a lifetime risk of approximately 50-60% of developing each of colorectal 
carcinoma (CRC) and endometrial carcinoma (EC), with a lower risk of 
ovarian carcinoma (OC) of 8-10%; OC is the third most frequent malignancy 
in women with LS (3-5). EC is the first or sentinel malignancy in more than 
half of those women with LS who develop cancer (6). A significant proportion 
of women with LS and EC go on to develop a second or further malignancies 
(7), the risks of which have been shown to be up to 55% and 15% 
respectively (8). Surveillance and preventative strategies aimed at the patient 
and susceptible family members results in a decreased incidence and 
substantially reduced mortality from LS-related cancers (7, 9-11).  
Screening for LS in all newly diagnosed EC patients therefore offers an 
opportunity to detect undiagnosed LS. EC has an excellent 5-year disease 
specific survival (12). As EC is often a sentinel event, this allows diagnosis 
before the development of potentially fatal malignancies such as CRC. Early 
diagnosis enables colorectal surveillance which, is known to improve the 
disease specific survival in CRC (3, 9, 10). In addition, cascade testing of 
family members allow the diagnosis of healthy pathological MMR mutation 
carriers and their subsequent enrolment into suitable surveillance 
programmes. 
Pathological MMR mutations lead to dysfunctional and structurally abnormal 
MMR proteins. This in turn brings about a detectable tumour phenotype with 
loss of MMR protein expression and a hypermutated tumour demonstrating 
microsatellite instability (1, 13). Screening for pathological MMR mutations 
can be carried out easily using readily available immunohistochemistry (IHC) 
for MMR proteins (Figures 1 and 2), or by MSI testing, or both (14-16). Overall 
only 2-3% of ECs occur in patients with LS, and clinical and morphological 
factors are not sensitive enough to allow targeted screening as cases would 
be missed regardless of the selection criteria used (17). Guidelines from 
several professional bodies and expert consensus groups therefore advocate 
universal screening for LS in all newly diagnosed EC cases (18-22) however 
there is wide variation in practice and a lack of universal agreement amongst 
pathologists (23, 24).  
The identification of MMR defective (MMRd) EC has implications beyond the 
detection of LS. ECs with acquired somatic pathological MMR mutations 
(alongside those with germline mutations) are susceptible to check point 
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inhibition treatments (25). Furthermore, the publication of the Cancer Genome 
Atlas (TCGA) Study and subsequent validation studies have shown that EC 
can be subclassified into 4 different molecular categories based on their 
mutational profiles, including one associated with MMRd that accounts for 
approximately 25% of EC (26-28). Tumors within the 4 molecular categories 
differ with respect to prognosis, and response to treatment. Therefore, 
universal screening of ECs enables tailored management and is of benefit 
despite LS screening.  
LS screening in all or selected cases of OC is more controversial. However, 
the risk of LS in patients with ovarian endometrioid or clear cell carcinoma is 
identical to that of patients with CRC or EC (29, 30); the risk of LS in patients 
with other OC histotypes is much lower (29, 31). 
Given the factors above, we undertook a survey amongst members of two 
large gynaecological pathology societies in order to assess the current 
understanding of LS in relation to gynaecological malignancy and the views of 
pathologists regarding screening for LS. We hoped this would provide critical 
information about the current clinical landscape with an international 
perspective.   
Methods: 
A collaborative multidisciplinary group was formed from members of the 
British Association of Gynaecological Pathologists (BAGP), International 
Society of Gynecological Pathologists (ISGyP) and invited experts, to design 
questions that would explore variation in attitudes and current practices 
related to LS screening in gynecological cancers. The group included 4 
pathologists (NS, WGM, MJA, CBG), 2 clinical geneticists (DGE, LS), 3 
gynaecological surgeons (NR, EC, RM) and 1 molecular geneticist (IF). We 
also utilised Lynch syndrome UK (a patient advocate group) to ensure our 
questionnaire content captured the key concerns of both clinical and patient 
stake holders. After taking opinions from the experts, the questions were 
formulated and sent for review to the panel for comments. These were then 
sent to members of the council of the BAGP and ISGyP, finalised by two 
senior authors (EC and NS) and approved by the panel for sending out to the 
memberships of BAGP and ISGyP. The link to the electronic survey hosted on 
the University of Manchester website was sent to all members of the BAGP 
and the ISGyP between January and June 2017.  
The survey was composed of 36 questions and included a combination of 
dichotomous, multiple choice and open-ended format questions. The 
questions were separated into those relating to the respondent, those 
assessing background knowledge, those assessing current practice and lastly 
those exploring the opinions on future guidelines. The survey questions are 
tabulated in Supplementary Table 1.  
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Responses from the two groups surveyed were compiled and the results 
analyzed. Any survey that was returned incomplete was excluded from 
analysis. 
Results: 
A total of 52 ISGyP members and 48 BAGP members responded. These 
represented a minority of the 177 (27%) BAGP and 345 (14%) ISGyP 
members to whom the link was emailed. Members of ISGyP received the 
survey after the BAGP survey had been closed; while some participants may 
have had the opportunity to respond on both occasions, given the low 
response rate overall, and the differences in the responses as below, this 
seems unlikely. Twenty responses were excluded due to incomplete data (15 
of the responders reported having no knowledge LS and did not offer 
responses to further questions). There were 44 complete surveys from ISGyP 
and 36 from BAGP members giving a total of 80 completed datasets.  
Background information about the respondent 
Responses were received from the UK and mainland Europe, Asia, North and 
South America, Africa and Australia. Of the BAGP respondents, who had 
obtained their primary medical qualification in a variety of countries worldwide, 
30/36 had obtained their higher specialist training in the UK, and all of the 
remainder in mainland Europe. Of the included ISGyP responses, 24 (55%) 
were from North America and 15 (34%) from Europe, with the remainder 
being from Australia (3, 7%), South America and Africa (1 respondent (2%) 
each). Half of responders were based in an academic centre/teaching hospital 
affiliated to a medical school or tertiary referral center, with smaller numbers 
based in private hospitals or laboratories or district general hospitals. Thirty 
nine percent (n=31) were based in a cancer center or unit. The majority of 
responders (74%, n=59) described themselves as practicing in many areas 
with a special interest/responsibility in gynaecological pathology. Twenty five 
percent (n=20) solely practiced gynaecological pathology.  
Half of pathologists (n=40) reported diagnosing over 100 new cases of EC 
annually (including referrals).  
Baseline knowledge about Lynch Syndrome 
Of note, fifteen percent of those pathologists who had initially responded, had 
no knowledge of LS and were therefore removed from further analysis. Those 
included in the analysis were aware of LS. When asked to select associated 
malignancies, 100% included CRC. Only 1% (n=1) and 3% (n=2) did not 
include EC and OC respectively.  
The majority of pathologists (70%, n=56) were aware of guidelines such as 
those of the Society of Gynecologic Oncologists(31) relating to the screening 
7  
of LS. Thirty percent (n=24) of the practitioners questioned reported being 
unfamiliar with any guidelines. Fourteen percent (n=11) were not aware of the 
recently published TCGA molecular classification of EC.  
When asked ‘roughly what proportion of sporadic or germline (LS) DNA 
mismatch repair gene defects can be detected by IHC alone for mismatch 
repair gene proteins’, 81% of respondents (n=65) opted for a proportion 
above 75% with 43% (n=34) responders choosing >90%.  
Current practice regarding screening for mismatch repair defects and 
microsatellite instability 
Only three percent (n=2) respondents never carried out MMR IHC on EC 
cases, and 36% (n=29) tested all new cases. There was a striking difference 
in the proportion of pathologists currently carrying out universal MMR testing 
in all cases of EC between respondents from North America (19/24, 79%) and 
those from all other regions (9/56, 16%). Amongst respondents who carried 
out LS screening in selected cases, the indications varied widely as 
summarized in Table 1. There was an overall majority amongst BAGP and 
ISGyP members in favor of universal screening for LS in new cases of EC, 
with less agreement on reflex screening in OC (Figure 3).  
Of the pathologists who undertook MMR IHC for initial screening, 81% (n=65) 
requested all four markers (MLH1, PMS2, MSH2, MSH6) in the first instance. 
Far fewer (8%, n=10) initially requested 2 markers with a third marker or full 
panel subsequently performed if there is loss of staining or equivocal staining 
with any marker.  
Nearly half of those questioned had access to MLH1 promoter methylation 
testing (if IHC revealed a loss of MLH1), either within their institute or 
regionally (25% (n=20) and 36% (n=29) respectively). Fourteen percent 
(n=11) respondents had no access to this testing. Seventy percent (n=56) had 
access to MSI testing regionally and/or within their institution. These 
respondents were employed in both University and non-University hospitals.   
When questioned further regarding initiating testing for MSI in their institution, 
32 of 56 (57%) pathologists with access to testing did so only in those cases 
where the initial IHC was normal, equivocal or difficult to interpret. Only four of 
56 (7%) sent all samples for MSI regardless of the IHC result. 
A majority of respondents (62%, n=60,) had germline MMR gene sequencing 
available to them at least on a regional level. Eight percent (n=6) of 
responders had no access, and 29% (n=23) were unsure.  
Gross specimen handling  
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Over two thirds (68% n=54) of the pathologists were based in departments 
that had received prophylactic hysterectomy and salpingo-oophorectomy 
specimens for LS cases. The majority of these (60%, n=48) reported that 
there was a departmental standard protocol for dissecting and sampling these 
specimens; in the remainder, no protocol was in place.  
Consensus regarding universal screening of new EC for Lynch Syndrome 
There was overwhelming agreement for universal screening of all new EC 
cases for LS with 71% (n=57) in favor of this approach (41% strongly 
agreeing). When the response was ‘neutral’ or ‘disagree’, reasons cited 
included cost implications and the relative low incidence of LS-related EC. Of 
note, those who disagreed with universal screening were employed in 
university and non-university hospitals.  When questioned about the ideal 
method for universal screening of new cases of EC, 59% (n=47) advocated 
the use of IHC alone while 29% (n=23) favored combined IHC and MSI 
testing (the remainder were unsure about a preferred strategy). The majority 
of those that advocated IHC and MSI were employed in a University hospital 
(n=14).The preferred method for initial screening of new cases of EC varied 
according to the group surveyed with ISGyP members favoring IHC alone 
whereas, amongst BAGP members, a combination of IHC and MSI testing 
was the preferred option (Figure 4).   
Cost effectiveness was again provided as a rationale for IHC (n=28) only 
while others were guided by previous experience (n=7).  
On the question of whether consent for IHC testing was required in new cases 
of EC, 38% (n=28) held the opinion that consent should be gained from the 
patient before MMR IHC testing.  
The pathologists were then asked ‘if universal MMR IHC was recommended 
for EC which of the following would serve as an initial screening test in your 
opinion?’. Sixty four percent (n=51) responded that testing for all four MMR 
markers should be undertaken in the first instance. All of those who had a 
preference for 2 protein (n=2) IHC screening (MSH6 and PMS2 with reflex 
four protein IHC for those found to be deficient) both worked in a University 
hospital. When asked if their respective laboratories had the capability to 
absorb the time and cost demands of performing MMR immunohistochemistry 
on all new EC, over half (56% n=45) stated that they would. Thirty three 
percent (n=26) however felt that this would not be practical with 11% (n=9) 
strongly stating that their laboratory did not have this capacity.  Figure 5 
shows the percentage of BAGP and ISGyP respondents who agreed and 
disagreed with the statement regarding laboratory capability in the event of 
the introduction of universal LS testing for new EC cases.  
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There was a divergence of opinion regarding the centralization of IHC 
screening and molecular analysis (e.g. microsatellite instability analysis) in the 
diagnostic pathway in the event of introduction of universal screening. Almost 
equal numbers agreed (44% n=35) or disagreed (39% n=31) with 
centralization, interestingly those who agreed with centralization mostly 
(n=23) employees of a University hospital.  
There was almost universal acceptance of the need for standardized reporting 
terminology for MMR immunohistochemistry with only one responder 
indicating neutrality when asked about the utility of this approach. Multiple 
answers were provided when asked about who should lead on referring EC 
patients with abnormal screening results for LS germline testing.  In the 
majority of cases, multiple responses were given with the gynecological 
oncology multidisciplinary team /tumor board meeting widely identified as the 
preferred option. Ten responders felt that the pathologist should be solely 
responsible for referral.  
Universal screening of new ovarian carcinomas for LS 
Attitudes towards the screening of women with a new diagnosis of OC were 
also assessed. There was a tendency towards disagreement regarding the 
introduction of universal screening amongst BAGP and ISGyP members 
surveyed (figure 1). Overall, 83% (n=66) of responders were neutral, 
disagreed or strongly disagreed with the introduction of universal screening in 
this specific context. When questioned further, responders who disagreed 
cited reasons relating to incidence, cost-effectiveness and the need to base 
decisions on tumor morphology (i.e. endometrioid and clear cell types) rather 
than employ a universal screening approach.  
 
Discussion 
This survey has offered insights into current knowledge and practice with 
respect to screening EC and OC for LS among ISyGP and BAGP members. 
As with similar studies in the past, this shows continuing variation in attitudes 
and practices (23, 24). It is acknowledged that the survey had a poor 
response overall from both societies, a reflection itself perhaps of the lack of 
awareness in regard to this issue. Considering that these responses are from 
those who are aware of the implications of screening, a particularly striking 
finding is the difference between responses obtained from the two societies 
with respect to universal screening for LS in EC. This is likely related to the 
lack of clear guidelines and resources for testing. In the United Kingdom, 
universal LS screening for colorectal cancers has been recommended by the 
National Institute of Health and Care Excellence (32) since February 2017, 
however a similar approach for EC is currently under assessment with a 
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decision anticipated before the end of 2020. In the absence of mandatory 
testing, UK laboratories have to absorb the cost of additional 
immunohistochemistry or molecular testing, while differences in adoption of 
guidelines and/or funding may explain the easier access and greater support 
of universal testing in other countries. 
Responders had a good awareness of the association between LS and the 
subsequent development of EC; less encouraging however was the finding 
that 7% of those who completed the survey were unaware of published 
guidelines such as those produced by The Society of Gynecologic 
Oncologists, the National Comprehensive Cancer Network and the Royal 
College of Pathologists of UK. It is also important to note that 15 responses 
were excluded because the respondents reported having ‘no knowledge of 
LS’. Sixteen percent of those completing the survey were unaware of the 
recently published TCGA molecular classification of EC. This suggests that 
there is a need to further disseminate ‘best practice’ recommendations 
regarding these hereditary cancers. Furthermore, it highlights the disconnect 
between research and clinical practice; the identification of MMRd tumors has 
key prognostic and therapeutic implications which could be denied to patients 
if clinicians are unaware of them (25, 26).    
A high percentage of the pathologists who undertook the survey were 
involved in screening for LS in new cases of EC and they were 
overwhelmingly likely to use IHC with the four markers MLH1, PMS2, MSH2, 
MSH6. Over 70% were in favor of universal screening using IHC as the 
preferred technique; cost and previous experience with this technique were 
given as reasons for this choice over the combination of a combined IHC/MSI 
approach. Interpretation of MMR IHC is relatively straightforward provided that 
standardised and external quality assured protocols are in use and there is 
due regard to pitfalls in interpretation (16). There was strong support for 
standardized reporting of MMR IHC. As a result of this and as part of a larger 
consensus project on LS screening, standardised terminology is 
recommended which is presented in table 2 (33). Of note was the disparity 
between access to testing due to working in a non-University hospital setting. 
This health inequality remains a key barrier to universal screening of EC for 
LS. It is potentially an argument for centralization of such testing so as to 
assure access for all. In addition, it may prove cost effective to have central 
referral and therefore efficient resource use, although further research 
exploring this is required.  
An interesting finding was the significant proportion of pathologists who 
believed that individual patient consent should be granted before initiating 
MMR IHC testing. In the event of universal screening, approximately one third 
of pathologists held the opinion that consent should be sought before 
proceeding with IHC. This has been an area of controversy for years, with 
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advocates for universal screening without consent arguing that the results of 
MMR IHC only indicate an increased likelihood of LS, and affording the 
patient the option of undergoing definitive testing. It is the opinion of the 
authors that testing that yields somatic and not germline information, gives 
information about the biology of the tumour and not that of the patient.  In this 
way, it is arguably no different from reporting an EC arising in the lower 
uterine segment, with a prominent peritumoral and intratumoral lymphocytic 
infiltrate, in that such a patient would also be at increased risk of LS. With the 
constantly changing face of genomic medicine, ethical considerations 
regarding the implications of these investigations are likely to become more 
contentious. This is an area where guidance and formulation of a 
standardized approach may be of benefit. With only 2-3% of EC cases 
occurring in LS patients, taking individual consent prior to a screening test 
would place an unnecessary burden on the patient and the clinical team; it is 
far more preferable to only seek consent for definitive germline testing in 
women who are positive on their screening test. A positive screening test 
does not equate to LS; approximately 50% of cases who are screen-positive 
following MMR IHC combined with MLH1 promoter methylation testing will 
show positive results on germline testing, the remainder being the result of 
false negative MMR IHC, bi-allelic somatic mutations and epigenetic 
phenomena, as well as false negative germline testing results (13, 34, 35). 
From the viewpoint of TCGA disease classification, the situation is analogous 
to performing p53 IHC testing to help delineate serous-like EC; the presence 
of TP53 mutation is sought in the tumour and while this could be indicative of 
Li-Fraumeni syndrome, consent is not taken a priori from the patient.    
 
The practical implications of universal testing in cases of newly diagnosed EC 
were investigated with questions regarding access to IHC and relevant 
genomic testing. An encouraging finding was that the majority of respondents 
reported that they believed their laboratory would be able to cope with the 
practical and financial impact of the introduction of universal screening. This 
was not so evident outside University hospital settings.   Thirty-one 
responders reported having no access to, or being unaware of arrangements 
for MLH1 promoter methylation testing. MSI testing, however, was more likely 
to be available with 70% having access. In regions with access to MLH1 
promotor methylation testing, an equivocal and/ or difficult to interpret IHC 
result was often given as the rationale for requesting MSI testing.  Eight 
pathologists had no access to germline MMR sequencing and a further 23 
reported being unaware of the availability of this service in their region. These 
results highlight the variation in molecular services available to pathologists 
involved in the diagnosis and management of women with hereditary 
endometrial and ovarian malignancies and the barriers to testing posed by 
global health inequality.  
Most pathologists who responded to the survey were receiving risk-reducing 
hysterectomy and salpingo-oophorectomy specimens and while the majority 
had an agreed protocol in place for the processing of these surgical 
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specimens, nearly 20% had no protocol. It could be argued that if these 
specimens are handled as routine ‘benign’ cases, they are likely to be less 
widely sampled and this may have implications for the detection of occult 
malignancy.  This warrants the adoption of specific guidance. The recently 
published ISGyP recommendations for specimen handling in endometrial 
carcinoma, carried out as part of a project on endometrial carcinoma 
reporting, includes guidance on LS cases (36). Similar recommendations 
have also been published previously (37) and these include sampling the 
entire endometrium, including the lower uterine segment, fallopian tubes and 
ovaries with representative sampling of the cervix. 
There was less agreement when the pathologists were questioned about 
universal screening of newly diagnosed OC with divergent opinions 
expressed. The disagreement, at least in part, can be explained by the 
differing likelihood of finding MMR deficiency in different OC histotypes, with a 
very low prevalence in the most common tumor type high-grade serous 
carcinomas. Many of the respondents specifically stated that screening this 
subset of OC patients was not indicated. Resource issues were also cited as 
a reason why this should not be adopted as a strategy. Given the increasing 
availability and diminishing costs of next generation sequencing, in which 
panels of genes are tested simultaneously, together with the 15-20% 
possibility of patients with high-grade serous carcinoma having germline 
mutations in genes associated with Hereditary Breast and Ovarian Cancer 
syndrome, it may be preferable to proceed directly to this testing in all newly 
diagnosed OC patients, using a gene panel that includes genes associated 
with LS and Hereditary Breast and  Ovarian Cancer. 
As with all surveys, this one has important limitations. Only a minority of 
members of both societies responded to the survey. The respondents are 
self-selected with a likelihood of having an interest in this field; it is therefore 
possible that this is not a true representation of current practice and that 
current coverage of and support for LS screening in EC is even lower than the 
results suggest. The BAGP survey preceded that within ISGyP and some 
questions therefore slightly differed; for example ISGyP memebrs were asked 
in which country they practiced while BAGP members largely work within the 
UK and were asked their country of primary and specialist qualification; the 
data were insufficient to draw meaningful comparisons between practices in 
different nations. 
Conclusions 
Despite good evidence that screening for LS in EC has high potential for 
reducing morbidity, mortality and healthcare costs, and the wide availability of 
screening tests, there remains huge variation in the approach to screening. 
Pathologists need to be aware of the implications of LS screening for the 
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patient and her family. Standardised and external quality assured protocols 
should be developed and adopted for LS screening in EC. The ISGyP has 
recently recommended that all newly diagnosed cases of EC undergo testing 
for LS using IHC or molecular testing as the initial modality (21, 22). We also 
suggest that all newly diagnosed patients with ovarian endometrioid or clear 
cell carcinoma are similarly screened for LS. 
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Figure Legends 
 
Figure 1a. Normal expression of mismatch repair proteins in well-fixed 
specimen. This example of MLH1 staining in a biopsy serves to demonstrate 
typical MMR protein expression as diffuse strong nuclear staining, typically 
stronger than the background stromal nuclei that serve as an internal control. 
Figure 1b. MSH2 loss in a case of known germline MSH2 mutation. 
Figure 2a. MMR protein staining is fixation sensitive; in this example of 
normal MLH1 staining the nuclei stain more weakly than in the biopsy 
demonstrated in Figure 1a. The stroma and normal non-neoplastic 
endometrium serve as internal controls. 
Figure 2b. In poorly fixed specimen due attention should be paid to the 
internal control which is weaker. In this example of germline MSH2 mutation, 
staining for MSH2 protein is absent in the presence of positive, albeit weak 
staining in background stromal and endometrial glandular epithelial cells. 
Figure 3. Bar chart showing responses amongst BAGP and ISGyP members 
regarding the introduction of universal screening for Lynch syndrome for new 
cases of endometrial and ovarian malignancy.  
Figure 4. Bar chart showing the favored screening test for new cases of 
endometrial malignancy amongst BAGP and ISGyP members.  
Figure 5. Bar chart showing the responses of BAGP and ISGyP members 
when questioned about whether their laboratory would be able to absorb 
(agree) or unable to absorb (disagree) the demands of universal testing for 
Lynch Syndrome for new cases of endometrial carcinoma.   
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Table 1: Reasons for carrying out mismatch report protein immunohistochemistry (MMR IHC) in cases of endometrial cancer (EC)  
Basis for carrying out MMR IHC  Number (%) of 
BAGP 
respondents 
(n=36) 
Number (%) of 
ISGyP 
respondents 
(n=44) 
All EC regardless of 
clinical/pathological features 
4 (11) 25 (57) 
Selected testing* 29 (81) 17 (39)  Age of patient ≤50/≤60/≤70  years 19/6/2 (53/17/6) 9/4/3 (20/9/7)  Past history of bowel cancer/any cancer  21/3 (64/8) 12/4 (27/9)  Meets Amsterdam or Bethesda criteria 12 (33) 7 (16)  Morphology, e.g. Tumour infiltrating lymphocytes, or location of tumor 26 (72) 12 (27)  Specific histotypes of endometrial cancer  1 (3) 7 (16)  Synchronous cancer   25 (69)  11 (25)  Strong family history 18 (50) 12 (27) 
Never 0 (0) 2 (4) 
Clinical/MDT/Tumor board request 
only 
3 (8) 0 (0)  
 
  
Table 2: Recommended Terminology20 for Reporting Mismatch Repair Protein Immunohistochemistry (MMR IHC) +/- MLH1 promoter methylation resultsa,b,c,d  
MMR result  Recommended report Normal, MLH1, 
PMS2, MSH2 and 
MSH6 tested MMR IHC Normal:  The tumour cells show normal nuclear staining for MLH1, 
PMS2, MSH2 and MSH6.  
 
Conclusion: There is no immunohistochemical evidence of 
a mismatch repair deficiency*.  
 Normal, only 
MSH6 and PMS2 tested MMR IHC Normal:  The tumour cells show normal nuclear staining for PMS2 
and MSH6.  
 
Conclusion: There is no immunohistochemical evidence of 
a mismatch repair deficiency*.   
Abnormal, MSH6 loss MMR IHC Abnormal, MSH6 loss:   
The tumour cells show loss of expression of the mismatch 
repair protein MSH6 (with normal nuclear staining for 
MLH1, MSH2 and PMS2).  
 
Conclusion: This mismatch repair deficiency is associated 
with Lynch and related syndromes.  
 
This patient should be referred to Clinical Genetics 
services.  
Abnormal, PMS2 loss MMR IHC Abnormal, PMS2 loss:   
The tumour cells show loss of expression of the mismatch 
repair protein PMS2 (with normal nuclear staining for 
MLH1, MSH2 and MSH6). 
 
Conclusion: This mismatch repair deficiency is associated 
with Lynch and related syndromes.  
 
This patient should be referred to Clinical Genetics 
services.  
Abnormal, MSH2 
and MSH6 loss MMR IHC Abnormal, MSH2 loss:   
The tumour cells show loss of expression of the mismatch 
repair proteins MSH2 and MSH6 (with normal nuclear 
staining for MLH1 and PMS2).  
 
Conclusion: This mismatch repair deficiency is associated 
with Lynch and related syndromes.  
 
This patient should be referred to Clinical Genetics 
services.    Abnormal, MLH1 
and PMS2 loss, 
MLH1 promoter hypermethylation absent 
MMR abnormality, MLH1 loss and MLH1 Promoter 
hypermethylation absent: 
 
The tumour cells show loss of expression of the mismatch 
repair proteins MLH1 and PMS2 (with normal nuclear 
staining for MSH2 and MSH6). MLH1 promoter 
hypermethylation is not present.  
 
Conclusion: While this mismatch repair deficiency could 
be sporadic, it is probable that this mismatch repair 
deficiency is due to Lynch or related syndromes.   
 
This patient should be referred to Clinical Genetics 
services.  Abnormal, MLH1 
and PMS2 loss, 
MLH1 promoter hypermethylation present 
MMR abnormality, MLH1 loss and MLH1 Promoter 
Hypermethylation present: 
 
The tumour cells show loss of expression of the mismatch 
repair proteins MLH1 and PMS2 (with normal nuclear 
staining for MSH2 and MSH6). The MLH1 promoter 
shows hypermethylation is present in the tumour.  
 
Conclusion: This combination indicates that this mismatch 
repair deficiency is almost certainly sporadic rather than 
due to Lynch Syndrome.  
 
This patient does not require referral to Clinical 
Genetics services*. 
 Abnormal, MLH1 
and PMS2 loss, 
MLH1 promoter hypermethylation not tested 
MMR abnormality, MLH1 loss and MLH1 Promoter 
hypermethylation not tested:  
 
The tumour cells show loss of expression of the mismatch 
repair proteins MLH1 and PMS2 (with normal nuclear 
staining for MSH2 and MSH6). MLH1 promoter 
hypermethylation has not been tested.  
 
Conclusion: This pattern is likely to be sporadic, although 
it is possible that this mismatch repair deficiency is due to 
Lynch or related syndromes. Testing for MLH1 Promoter 
hypermethylation is recommended OR this patient 
may be referred to Clinical Genetics services. 
 Abnormal, MLH1 
and PMS2 loss, 
MLH1 promoter hypermethylation pending 
MMR abnormality, MLH1 loss and MLH1 Promoter 
Hypermethylation testing results pending:  
The tumour cells show loss of expression of the mismatch 
repair proteins MLH1 and PMS2 (with normal nuclear 
staining for MSH2 and MSH6). MLH1 promoter 
hypermethylation testing in the tumour has been 
requested. 
Conclusion: This pattern of mismatch repair deficiency 
may be either sporadic or due to Lynch or related 
syndromes – the result of testing for MLH1 promoter 
hypermethylation will provide further information. A 
supplementary report will be issued when these results 
become available.  
*Referral to Clinical Genetics services should be considered despite this 
result in the presence of a strong family/clinical history.  
aFor referral laboratories only reporting mismatch repair status the report 
should include:  
Specimen type:  
Site of sample:  
Diagnosis: 
Overall cellularity (biopsy samples only): High/average/low 
Percentage neoplastic nuclei in test area for DNA extraction:  
 
bGood fixation is important for obtaining reliable and reproducible patterns of 
MMR expression by IHC and can be evaluated by assessing MMR expression 
by internal control cells. Pre-operative biopsies are often better fixed than 
hysterectomy specimens and may be considered as a better sample for MMR 
IHC testing, depending on availability. MMR IHC should be reported only in 
the presence of positive internal control cells, such as stromal cells or 
lymphoid cells, that are immediately adjacent to the tumour cells under 
analysis; it must be stated if there is no internal control for comparison. 
 
cRare abnormalities of mismatch repair protein expression are not included in 
this table and these may be reported as free text where present; examples 
include weak/patchy/cytoplasmic/punctate or dot-like nuclear patterns of 
abnormal MMR expression, subclonal/heterogeneous patterns of MMR 
staining abnormality, and loss of expression of different combinations of MMR 
proteins (other than the expected MLH1 & PMS2 – or – MSH2 & MSH6 
combinations). 
 
dThe molecular mechanism for the strong association of BRAF mutation with 
CRC harbouring somatic MLH1 hypermethylation is incompletely 
understood  but appears to be tissue/tumour-specific; unlike algorithms in use 
for CRC, BRAF immunohistochemistry or sequencing cannot be used as a 
proxy for somatic MLH1 hypermethylation in gynecological cancers, as 
oncogenic BRAF mutations occur so rarely in these. 
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